We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Treatment of Asymptomatic Toxocariasis With Albendazole in Children

This study is ongoing, but not recruiting participants.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00755560
First Posted: September 19, 2008
Last Update Posted: February 19, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
The Hospital for Sick Children
Information provided by (Responsible Party):
Dr Jaime Altcheh, Hospital de Niños R. Gutierrez de Buenos Aires
  Purpose
The purpose of this study is to evaluate effectiveness of albendazole in the treatment of the asymptomatic infection with the parasite Toxocara in children. Treatment response is defined as a reduction in the number of eosinophils in blood. The study drug will be compared to placebo and randomly assigned in a double blind manner. Follow up will be prospective. 50 children (25 per group) will be enrolled in the study.

Condition Intervention Phase
Toxocariasis Drug: Albendazole Drug: Placebo Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Treatment of Asymptomatic Toxocariasis With Albendazole in Children. A Prospective, Randomized, Placebo-controlled Clinical Trial

Resource links provided by NLM:


Further study details as provided by Dr Jaime Altcheh, Hospital de Niños R. Gutierrez de Buenos Aires:

Primary Outcome Measures:
  • Mean absolute reduction in eosinophil count from baseline [ Time Frame: 12 months after treatment ]

Secondary Outcome Measures:
  • Reduction in eosinophil count in more than 60% from baseline [ Time Frame: 1 year ]
  • Incidence of adverse drug events [ Time Frame: 3, 6, 9 and 12 months after treatment ]
  • Mean absolute reduction in eosinophil count [ Time Frame: 3, 6, 9 months after treatment ]

Estimated Enrollment: 50
Study Start Date: September 2008
Estimated Study Completion Date: July 2017
Primary Completion Date: July 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Albendazole
Albendazole 10 - 15 mg/kg/day BID for 15 days
Drug: Albendazole
Albendazole 10 - 15 mg/kg/day BID for 15 days
Placebo Comparator: Placebo
Placebo BID for 15 days
Drug: Placebo
Placebo BID for 15 days

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   2 Years to 15 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Pediatric ambulatory patients with asymptomatic toxocariasis
  • Children 2 - 15 years old
  • Absolute eosinophil count > 1100 / mm3
  • Normal ophthalmoscopy

Exclusion Criteria:

  • Treatment with a benzimidazole in the previous year
  • Infection by other nematodes (Ascaris lumbricoides, strongyloides stercoralis, uncinarias, Trichuris trichuria)
  • Symptomatic patients (prolonged fever, acute pneumonitis, hepatomegaly, splenomegaly, ocular compromise due to toxocara)
  • Concomitant diseases
  • Immunocompromised patients
  • Altered liver or kidney function
  • Pregnancy
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00755560


Locations
Argentina
Parasitology Division, Children's Hospital "R Gutierrez" of Buenos Aires
Buenos Aires, Argentina, 1425
Sponsors and Collaborators
Hospital de Niños R. Gutierrez de Buenos Aires
The Hospital for Sick Children
Investigators
Study Chair: Jaime Altcheh, MD Parasitology Division, Children's Hospital "R Gutierrez" of Buenos Aires
Principal Investigator: Hector Freilij, MD Parasitology Division, Children's Hospital "R Gutierrez" of Buenos Aires
  More Information

Responsible Party: Dr Jaime Altcheh, Service Head, Parasitology and Chagas Service, Hospital de Niños R. Gutierrez de Buenos Aires
ClinicalTrials.gov Identifier: NCT00755560     History of Changes
Other Study ID Numbers: TOXOCARA-ALBENDAZOLE
First Submitted: September 17, 2008
First Posted: September 19, 2008
Last Update Posted: February 19, 2016
Last Verified: February 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Keywords provided by Dr Jaime Altcheh, Hospital de Niños R. Gutierrez de Buenos Aires:
Toxocara
Pediatrics
Albendazole
eosinophilia
parasitology
pediatric clinical pharmacology

Additional relevant MeSH terms:
Toxocariasis
Helminthiasis, Animal
Helminthiasis
Parasitic Diseases
Ascaridida Infections
Secernentea Infections
Nematode Infections
Parasitic Diseases, Animal
Albendazole
Anthelmintics
Antiparasitic Agents
Anti-Infective Agents
Anticestodal Agents
Antiplatyhelmintic Agents
Antiprotozoal Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents